Sitagliptin, a pyrazine derivative with triazole moiety, is a hypoglycaemic agent for type II diabetes patients via inhibition of dipeptidyl-peptidase IV [35]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.